Carlsmed, Inc. CARL 深 滬
交易中 02-09 10:50:21 美东时间
11.475
-0.195
-1.67%
華盛通- 最 高12.3399
- 今 開11.60
- 成交量 1.12万股
- 最 低 11.295
- 昨 收 11.67
- 總市值 3.04亿
- 52周最高 17.19
- 市盈率 靜 --
- 換手率 0.04%
- 52周最低 11.10
- 委 比 9.45%
- 總股本 2651.63万
- 歷史最高 17.19
- 量 比 1.06
- 振 幅 8.95%
- 歷史最低 11.10
- 每 手 1
- 風險率 0.97%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Carlsmed shares are trading higher. The company announced preliminary Q4 and FY25 revenue guidance.
Carlsmed shares are trading higher. The company announced preliminary Q4 and FY...
01-13 02:11
Carlsmed Raises FY2025 Sales Guidance from $49.000M-$50.000M to $50.500M vs $49.651M Est
Carlsmed (NASDAQ:CARL) raises FY2025 sales outlook from $49.000 million-$50.000 million to $50.500 million vs $49.651 million estimate.
01-12 21:22
Carlsmed Sees Q4 Sales $15.200M vs $14.300M Est
Carlsmed (NASDAQ:CARL) sees Q4 sales of $15.200 million vs $14.300 million analyst estimate.
01-12 21:21
Carlsmed Reports Q4 2025 Revenue Of ~$15.2M; Full-Year 2025 Revenue Of ~$50.5M
Fourth quarter 2025 revenue of ~$15.2 million, representing ~61% growth over Q4 2024Full Year 2025 revenue of ~$50.5 million; representing ~86% growth over 2024CARLSBAD, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) --
01-12 21:16
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
BTIG Reiterates Buy on Carlsmed, Maintains $24 Price Target
BTIG analyst Ryan Zimmerman reiterates Carlsmed (NASDAQ:CARL) with a Buy and maintains $24 price target.
2025-12-15 19:52
Carlsmed Announces U.S. Commercial Launch Of Aprevo Technology Platform For Cervical Fusion Surgeries
Carlsmed, Inc. (NASDAQ:CARL) ("Carlsmed" or the "Company"), today announced the U.S. commercial launch of its aprevo® Technology Platform for cervical fusion surgeries. Surgeons involved in the clinical evaluation
2025-12-03 20:10
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
2025-11-10 10:22
BTIG Maintains Buy on Carlsmed, Raises Price Target to $24
BTIG analyst Ryan Zimmerman maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $21 to $24.
2025-11-07 17:29
